Barclays Upgrades Pfizer (PFE) to Overweight

November 29, 2016 6:44 AM EST
Get Alerts PFE Hot Sheet
Price: $32.03 -0.09%

Rating Summary:
    13 Buy, 12 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 5 | Down: 5 | New: 0
Trade PFE Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

(Updated - November 29, 2016 8:11 AM EST)

Barclays upgraded Pfizer (NYSE: PFE) from Equalweight to Overweight with a price target of $38.00. Analyst Geoff Meacham sees a higher chance that cash trapped outside the U.S. can be better utilized for productive M&A and return of capital to shareholders.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $31.54 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Upgrades

Related Entities

Barclays

Add Your Comment